Funding
OptoPath has been granted 6 000 000 euros over 9 years in the context of the Investissements d’Avenir (Investment for the future plan of the French government).
Beside equipment, Optopath was granted 1 800 000 euros by Inserm * for the construction of a dedicated building in the premises of the Neurocentre Magendie.
Inserm *: Institut National de la Santé et de la Recherche Médicale – National Institute of Health and Medical Research
